Olanzapine (5 mg) Plus Standard Triple Antiemetic Therapy for the Prevention of Multiple-Day Cisplatin Chemotherapy-Induced Nausea and Vomiting: A Prospective Randomized Controlled Study
Abstract Objective A prospective randomized controlled trial was conducted to compare 5 mg olanzapine plus standard triple antiemetic therapy for the prevention of nausea and vomiting induced by multiple-day cisplatin chemotherapy. Methods Patients received 3-day cisplatin-based chemotherapy(25mg/m2/d) were given either 5mg olanzapine quadruple therapy (aprepitant, tropisetron, dexamethasone) or 5mg olanzapine-based triplet therapy. The primary end-point was the complete response(CR) in the overall phase(OP)(0-120h) between quadruple regimen group and triplet regimen group. The secondary end-points were the CR in the acute phase(AP)(0-24h), delayed phase(DP)(25-120h) between two groups. The first time of vomiting was also compared by Kaplan-Meier curves. The impact of chemotherapy induced nausea and vomiting(CINV) on the quality of life was assessed by the Functional Living Index-Emesis(FLIE). Aprepitant-related adverse effects (AEs) was also recorded. Results (1) The primary end-point CR during overall phase was 76.0% (45/59) vs 67.0% (41/61) between the quadruple regimen group and triplet regimen group(P =0.271). The secondary end-point CR during the AP was significantly higher in the quadruple group than in the triple group, which was 100.0%(59/59) vs 93.0%(57/61)(P=0.045). The difference between the groups was especially greater in the delayed phase(quadruple group 76.0% (45/59) vs triple group 67.0%(41/61)(P=0.271)). The rate of patients who achieved total protection in the overall phase was also larger in the quadruple group than in the triple group(28.8% (17/59) vs 23.0%(14/61)(P=0.463)). During the OP, the incidence of no vomiting in quadruple group and triple group was 93.2%(55/59) vs 80.3%(49/61)(P=0.038)respectively.(2) Kaplan-Meier curves of time to first emesis were obviously longer in the quadruple group than in the triple group(P=0.031). According to FLIE, no impact of CINV on daily life was defined as total score of questionnaire >108, this study exhibited identical life quality in quadruple group and the triplet group.(3) The most common aprepitant- and olanzapine-related AEs included sedation, fatigue and constipation. The occurrences between two groups were identical. Conclusion It may been recommended that combined 5mg olanzapine with aprepitant, tropisetron, dexamethasone quadruple therapy for the prevention of multiple-day cisplatin induced nausea and vomiting due to the better CINV control rate and safety.